Seattle, WA – According to filings with the U.S. Securities and Exchange Commission, Silverback Therapeutics is raising $78,697,259.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Peter Thompson played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Silverback Therapeutics

Silverback Therapeutics is charting a new path for treating a range of severe diseases. We are developing therapies that act on fundamental biological pathways that underlie disease, but that modern medicine has not been able to fully harness until now. Our team brings together diverse perspectives and deep experience in drug discovery and development, allowing us to approach long-standing challenges in new ways. At the core of our pipeline is our proprietary ImmunoTAC technology, which is designed to create potent therapeutic molecules that can be systemically administered to patients but that act only at the sites of disease, sparing healthy tissues from unwanted side effects.

To learn more about Silverback Therapeutics, visit http://www.silverbacktx.com/

Contact:
Peter Thompson, Chief Executive Officer
206-456-2900
https://www.linkedin.com/in/peter-thompson-0b069a1b/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved